Get all premium features to the best stock analysis tool

Agreement Set to Expand BUZZ BOMB™ Distribution Across Natural, Specialty, and Mass Merchandiser Channels ESTERO, FL / ACCESS Newswire / March 19, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, and TruLife Distribution ("TruLife"), announced they have concluded an agreement under which TruLife will manage and coordinate the sales, distribution and merchandising of BUZZ BOMB™ to retailers nationwide. TruLife Distribution is a premier agency known for scaling high-growth health and wellness brands.

ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the leadership team with a distinguished career of scaling consumer brands and leading high-performance teams across the retail and beverage sectors.

ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health & Fitness (HFA) Show, scheduled for March 16-18 at the San Diego Convention Center. Aspire will feature its flagship caffeine product, BUZZ BOMB™, at the New Product Zone, a premier area of the event highlighting innovative solutions for the global fitness industry.

Convenient Size at the Convenience Store ESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), today announced that its subsidiary, Buzz Bomb Caffeine Company, is expanding its retail footprint with the launch of the BUZZ BOMB™ Convenience Store Pack. Convenience stores are where many of today's quick decisions happen, and the checkout counter plays a big role in those moments.

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset formulation planned for mid-2026.

BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival. ESTERO, FL / ACCESS Newswire / February 25, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced a massive expansion of its social media and digital marketing footprint for its wholly owned subsidiary, Buzz Bomb Caffeine Company.

Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed Aspire maintains listing on the Nasdaq ESTERO, FL / ACCESS Newswire / February 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it had received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1). The Company announced on February 10, 2026 that it had received a letter from Nasdaq that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.